Biotechnology

A French biopharma's leap in synthetic lipid production de-risks its lead drug, eyes a vast sepsis market, and creates new commercial avenues.

The pharma giant's acquisition of Excellergy and its first-in-class Exl-111 could revolutionize treatment for millions with severe, debilitating allergies.

Agenus prepares a crucial update on its BOT+BAL immunotherapy, a potential breakthrough for cancers resistant to current treatments. What will they reveal?

Crinetics Pharmaceuticals aims to disrupt Brazil's acromegaly treatment with Palsonify, a once-daily pill challenging the standard of monthly injections.

With critical data due in 2026 and a leaner financial strategy, Zentalis is advancing its targeted therapy for a hard-to-treat ovarian cancer.

At a key investor conference, Renibus is pitching its two Phase 3 drugs, including one with a strategic pivot after a challenging trial result.

A new report slams the FDA for blocking vital treatments with rising costs and denials, but the agency faces a complex reality of reform and internal pressure.

With $1B in funding and a new virtual cell model, Xaira Therapeutics hires a top dealmaker to turn its AI prowess into pharma partnerships.

A groundbreaking study of 78,000 people shows most with acne and psoriasis manage their conditions alone, outside the clinic. Here's what it means.

A new wave of drug-free hair restoration combines ancient botanicals with FDA-cleared light therapy, challenging the chemical-reliant status quo.

A US firm is bringing embryo screening for chronic diseases to major IVF networks, sparking debate on the future of family planning and genetic health.

A novel drug targeting aging cells shows early success in treating psoriasis, eczema, and skin aging, heralding a new era in dermatology.

A new partnership will embed real-world cell therapy manufacturing into NJIT's graduate program, aiming to fill a critical skills gap in the biotech industry.

Tanabe Pharma Canada's 'Letters to ALS' offers a raw, intimate look into the fight against the disease, strengthening community bonds through shared stories.

A key recommendation for the drug BIMZELX could soon give Quebec patients a powerful new weapon against the debilitating skin disease hidradenitis suppurativa.

A novel three-in-one antibody from CStone shows a 90% response rate in lung cancer and potent activity in 'cold tumors,' heralding a new era for immunotherapy.

PetaSight's acquisition of Babbage Insight aims to fix a broken system with an 'intelligent OS', tackling the 38% data discard rate in life sciences PMR.

A new lithium formula boosts brain delivery in a key trial, offering hope for safer, more effective treatments for Alzheimer's, bipolar disorder, and more.

A new RNA drug shows promise by reducing harmful belly fat while preserving muscle, but modest overall weight loss in early trials spooks investors.

A new partnership between Boehringer Ingelheim and the CT Science Center seeks to build a talent pipeline for the state's booming biopharma industry.